EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 537 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR Cancer Survivor Kicked Out Of Bridal Party Cause She Refused To... August 29, 2019 Regional Node Radiotherapy Significantly Reduced Breast Cancer Mortality and All-Cause Mortality... November 10, 2023 New Risk Model Aims to Reduce Breast Cancer Disparities in Black... December 6, 2021 Common Questions About COVID-19 and Cancer: Answers for Patients and Survivors June 25, 2020 Load more HOT NEWS Get to Know CaringBridge Intratumoural Administration of the Oncolytic Herpes Virus Shows Survival Benefit and... Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in... FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma
